[Correspondence] Suicidal Crisis: First Regulatory Approval of IV Racemic Ketamine

Why It Matters

The decision provides a rapid, evidence‑based pharmacological option for patients at imminent suicide risk, potentially closing a critical treatment gap in mental‑health care.

Key Takeaways

• France first to approve IV racemic ketamine for suicide.
• Dose: 0.5 mg/kg over 40 min, reduces ideation hours.
• Generic racemic ketamine cheaper than intranasal esketamine.
• Approval limited to hospitals, psychiatrist prescription, 3‑year review.
• Long‑term misuse and limited efficacy remain concerns.

Pulse Analysis

The approval of intravenous racemic ketamine in France marks a watershed moment for suicide prevention, a field long starved of rapid‑acting pharmacotherapies. Traditional antidepressants can take weeks to alleviate depressive symptoms, leaving a dangerous window for patients experiencing acute suicidal ideation. Over the past decade, randomized trials have consistently demonstrated that sub‑anaesthetic ketamine infusions can produce measurable reductions in suicidal thoughts within hours, offering clinicians a tangible tool to intervene during the most vulnerable moments. This evidence base, coupled with meta‑analyses confirming durability of effect for several days, underpins the regulatory confidence in the French decision.

Unlike intranasal esketamine, which is approved for treatment‑resistant depression in several jurisdictions, racemic ketamine delivers both enantiomers and is administered intravenously, a route that appears to confer stronger anti‑suicidal benefits. The generic formulation also carries a substantially lower price tag, making it more accessible for public hospitals and health systems operating under tight budgets. The French agency’s compassionate‑access framework mandates hospital‑based administration, psychiatrist oversight, and integration into multimodal care pathways, ensuring that the drug is used judiciously and monitored closely. A mandatory three‑year re‑evaluation will assess real‑world safety, efficacy, and potential diversion risks.

For the broader mental‑health landscape, France’s move could catalyze similar regulatory actions worldwide, prompting pharmaceutical companies to pursue formal approvals for racemic ketamine or other rapid‑acting agents. However, clinicians must balance short‑term gains with the drug’s known dissociative side effects and the risk of misuse. Robust pharmacovigilance, prospective registries, and continued investment in evidence‑based psychotherapies remain essential to prevent the treatment from eclipsing comprehensive suicide prevention strategies. As data accumulate, the medical community will better understand how to position ketamine within a layered, patient‑centered approach to crisis care.